Tecan Group AG · SIX:TECN
Tecan — FY2018 Earnings Presentation
31 slides from Tecan's earnings presentation, Mar 11, 2019
Slide 1: Full Year Results 2018 Analyst & Media Conference Call
Zurich, August 16 2017 Zurich, March 11 2019 Half Full Year Year Results Results2017 2018 ANALYST & MEDIA CONFERENCE CALL ANALYST & MEDIA CONFERENCE CALL
Slide 2: Speakers
Speakers Dr. David Martyr, CEO Dr. Rudolf Eugster, CFO Dr. Achim von Leoprechting, EVP, designated CEO 2
Slide 3: Agenda
Agenda INTRODUCTION FINANCIAL RESULTS OUTLOOK QUESTIONS AND ANSWERS 3
Slide 4: Financial Highlights 2018
Financial Highlights 2018 • Strong financial results in H2 and another very successful business year 2018 • Full year orders up by 10.3% in LC to CHF 627 million • With +7.4% LC and +6.8% LC organic, another year of strong sales growth • Total recurring revenues at 42% of sales • EBITDA margin w/o N
Slide 5: Operating Highlights 2018
Operating Highlights 2018 • Market launch of Fluent® Gx platform variant for regulated markets • Successful registration as a Class I medical device in the US • Strong demand, major lab chains ordering multiple instruments at once • Acquisition of NuGEN (Tecan Genomics) Fluent® Gx • Further expandin
Slide 6: Agenda
Agenda INTRODUCTION FINANCIAL RESULTS OUTLOOK QUESTIONS AND ANSWERS 6
Slide 7: 2018 Order Entry and Sales Performance
2018 Order Entry and Sales Performance ORDER ENTRY FY 2018 ORDER ENTRY FY 2018 VS. FY 2017 640 627.0 • +11.1% in CHF and +10.3% in LC 600 • Organic +9.8% in LC CHF (mio) 564.3 560 • Order backlog with clear double-digit % increase 520 ORDER ENTRY H2 2018 VS. H2 2017 480 • +19.9% in CHF and +20.0% in
Slide 8: 2018 Segment Sales
2018 Segment Sales SALES (IN CHF MILLIONS) LIFE SCIENCES BUSINESS: 340.0 2017 328.2 2018 FY • Sales +7.0% in CHF and +5.6% in LC 320.0 306.9 • Organic sales growth of 4.6% in LC 300.0 • Order entry increased with double-digit rate 280.0 265.6 260.0 H2 • Sales up by 11.3% in CHF and 10.8% higher in L
Slide 9: FY 2018 Regional Sales Development
FY 2018 Regional Sales Development YoY % YoY % +2.5% in LC +12.4% in LC +4.2% in CHF +15.6% in CHF EUROPE: Others • Both business segments growing strongly 2.9% • Substantial growth in Life Sciences Business in H2 NORTH AMERICA: Asia • Solid growth in Life Sciences Business 15.6% • Moderate growth i
Slide 10: FY 2018 Gross Profit
FY 2018 Gross Profit GROSS PROFIT (% = % OF SALES) 290 278.3 GROSS PROFIT INCREASED TO CHF 278.3M • CHF 13.4m or 5.1% above 2017 270 264.9 GROSS PROFIT MARGIN DOWN BY 140 BPS CHF (mio) 250 • Main effects contributing: • (–) Higher freight and logistics cost 48.3% 46.9% 230 • (–) Exchange rate impact
Slide 11: FY 2018 Cost Structure
FY 2018 Cost Structure OPERATING EXPENSES (% = % OF SALES) OPERATING EXPENSES GREW LESS THAN 192.6m SALES 200 186.8m (32.4%) (34.0%) 180 • Operating expenses down by 160 bps 160 84.2 89.1 • Sales & Marketing increased less than sales 140 (15.3%) (15.0%) despite continued investments in market units
Slide 12: FY 2018 EBITDA Margin Development
FY 2018 EBITDA Margin Development +100 bps 19.4% 19.1% 18.4% 18.6% -70 bps -80bps 2017 Reported One-time 2017 2018 increase 2018 Effects related 2018 Reported EBITDA Margin positive jumping-off w/o NuGEN EBITDA Margin to NuGEN EBITDA Margin tailwind EBITDA Margin w/o NuGEN acquisition (as guided) •
Slide 13: FY 2018 Reported EBIT and EBITDA
FY 2018 Reported EBIT and EBITDA EBIT AND EBITDA (IN CHF MILLIONS) 120 110.3 110 104.6 EBIT INCREASED TO CHF 88.6M 100 • 8.8m or 11.0% above 2017 88.6 90 2017 79.8 EBITDA GREW TO CHF 110.3M 80 2018 • CHF 5.7m or 5.4% above 2017 70 60 50 EBIT EBITDA EBIT AND EBITDA MARGIN (% = % OF SALES) EBIT MARGIN
Slide 14: FY 2018 Segment Profitability
FY 2018 Segment Profitability EBIT (IN CHF MILLIONS) LIFE SCIENCES BUSINESS: 60 • EBIT margin reached 14.8% 50.5 51.3 50 48.6 • Factors contributing include: 42.0 40 • (–) Higher freight and logistics cost 2017 30 • (–) Acquisition-related costs (NuGEN) 2018 20 • (–) Exchange rate impact • (+) Price
Slide 15: FY 2018 Net Profit
FY 2018 Net Profit NET PROFIT 75 70.7 NET PROFIT GREW LESS THAN SALES 70 65.9 • CHF 4.8m or 7.2% above 2017 65 NET PROFIT MARGIN ALMOST UNCHANGED 60 57.1 AT 11.9% CHF (mio) 54.5 55 EBIT INCREASE OF CHF 8.8M 48.8% 49.5% 50 BELOW EBIT LINE 45 • (–) CHF 4.4m lower financial result 40.2 40 • (+) Lower t
Slide 16: FY 2018 Basic Earnings per Share
FY 2018 Basic Earnings per Share BASIC EARNINGS PER SHARE EARNINGS PER SHARE INCREASED TO 7 CHF 6.02 6.02 6 5.67 AVERAGE NUMBER OF SHARES CHF / share 5.05 OUTSTANDING: 11.7M (2017: 11.6M) 5 4.74 48.8% 49.5% 4 3.63 INCREASE IN THE DIVIDEND FROM CHF 2.00 TO CHF 2.10 PER SHARE TO BE PROPOSED 48.8% 49.5
Slide 17: FY 2018 Cash Flow
FY 2018 Cash Flow +92.7 309.4 -78.4 296.8 -26.9 Cash at end of From Operations From Investments From Financing1 Cash at end 2017 of 2018 CASH FLOW FROM OPERATIONS OF CHF 92.7M (2017: CHF 99.4M) • Inventory increase of CHF 7.8m • Cash conversion of 15.6% of sales • Days Sales Outstanding down to 47 d
Slide 18: FY 2018 Key Figures
FY 2018 Key Figures 2017 2018 Δ IN % Order Entry (in CHF mio) 564.3 627.0 +11.1% Sales (in CHF mio) 548.6 593.8 +8.2% Sales in local currencies (in CHF mio) 552.6 593.8 +7.4% Gross Profit (in CHF mio) 264.9 278.3 +5.1% in % of sales 48.3% 46.9% Net R&D (in CHF mio) 51.1 51.1 +0.0% in % of sales 9.3%
Slide 19: Agenda
Agenda INTRODUCTION FINANCIAL RESULTS OUTLOOK QUESTIONS AND ANSWERS 19
Slide 20: Transition from Research to Diagnostics
Transition from Research to Diagnostics TECAN HAS A UNIQUE POSITION TO BRIDGE FROM RESEARCH TO DIAGNOSTICS SETTINGS LIFE SCIENCE RESEARCH LAB DEVELOPED TESTS (LDT) IN-VITRO DIAGNOSTICS Life Sciences Life Sciences Partnering Business Business Business Covering individual steps of a Sample-to-Result S
Slide 21: Accelerating Broad Genomics Strategy
Accelerating Broad Genomics Strategy LIFE SCIENCES BUSINESS OFFERING COMPLETE AUTOMATED SOLUTION FOR NGS LIBRARY PREP AND QC • Genomics applications continue to be a major growth driver for Tecan • Acquisition of NuGEN (now Tecan Genomics) provides new opportunities in NGS, the fastest growing field
Slide 22: DreamPrep the latest Fluent Dream
DreamPrep™ the latest Fluent Dream LIFE SCIENCES BUSINESS EMPOWERING APPLICATIONS IS IN FLUENT’S DNA • Jun 2014: Cell Biology • Feb 2015: Compound Management • Aug 2015: General genomics • Jan 2016: New Feature Wave • Nov 2017: Fluent “2018” • Since 2017: Basis for Partnering Business projects • Apr
Slide 23: DreamPrep: so what is it?
DreamPrep: so what is it? LIFE SCIENCES BUSINESS TECAN’S FASTEST KITS ON TECAN’S FASTEST PLATFORM Tecan Liquid Handler: Fluent Tecan Reader: Infinite® for QC step Tecan Genomics: Celero™ Reagents Tecan Expertise: Installation & Application Support • Simple add and incubate workflow with only 1 final
Slide 24: Coming Soon….
Coming Soon…. LIFE SCIENCES BUSINESS NEW EXCITING VARIANTS OF THE SPARK READER • New high-end advanced imaging product range • Launch expected H1 2019 24
Slide 25: Introspect Software
Introspect™ Software LIFE SCIENCES BUSINESS INCREASING LAB PRODUCTIVITY WITH UNPARALLELED INSIGHTS 25
Slide 26: Healthy Development Pipeline and Rich Funnel
Healthy Development Pipeline and Rich Funnel PARTNERING BUSINESS SEVERAL PLATFORM LAUNCHES EXPECTED FOR 2019, INCLUDING… PS-10 SAMPLE PREP SYSTEM * PYROTEC™ PRO ROBOTIC SOLUTION * FOR SYSMEX CORPORATION FOR LONZA • Highly automated, lexible sample prep • Fully automated, plate-based robotic solution
Slide 27: Financial Outlook for 2019
Financial Outlook for 2019 SALES DEVELOPMENT REPORTED OPERATING PROFIT (EBITDA) Growth in EBITDA 700 MSD to 130 margin of HSD range around 650 in LC 120 19%1 593.8 110.3 600 110 104.6 CHF (mio) 548.6 100 CHF (mio) 550 506.2 89.0 500 90 83.4 440.3 80 450 67.5 70 65.1 388.3 399.5 400 60 16.8% 16.9% 18
Slide 28: ——h—CkeeeThTF.)hl CC Dll a eee
——h—CkeeeThTF.)hl CC Dll a eee ps Capital Markets foe Day. ;
Slide 29: Q&A
Q&A IR IPAD APP CONTACT News, financial reports, Martin Braendle presentations, Vice President, Communications & IR videos and more Phone: +41 (0) 44 922 84 30 NEXT EVENTS 2019 investor@tecan.com April 16: Annual Shareholder Meeting www.tecan.com June 6: CMD August 15: Half Year Results 2019 29
Slide 30: i) ef mm x a HTT
i) ef mm 4 x a 3 HTT veal nf te, ; :
Slide 31: Tecan – Who we are
Tecan – Who we are Tecan (www.tecan.com) is a leading global provider of laboratory instruments and solutions in biopharmaceuticals, forensics and clinical diagnostics. The company specializes in the development, production and distribution of automated workflow solutions for laboratories in the lif